Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 298,736 shares at $0.76 ($233K) on 2022-02-02, disclosed to the SEC on 2022-02-03.
Scheduled sale ($233k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.78 | 288,320 | $225K | 96.6% |
| 2 | $0.76 | 10,416 | $8K | 3.4% |
| Total | $0.78 avg | 298,736 | $233K | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |